Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Table 4 Rapamycin plus sorafenib is more effective than single agent rapamycin in subcutaneous Tsc2^-/- tumors

	Untreated	Rapamycin	Sorafenib	Combination Rapamycin plus Sorafenib
Number of mice (n)	6	5	6	5
Median survival (days)	24.5	46	19.5	53
P value (survival)	-	0.0014*	NS*	0.0014* 0.0018^#
Day 16, average tumor volume (mm³)	1454 ± 215	284 ± 52	2209 ± 499	293 ± 68
P value (day 16)	-	0.0007*	NS*	0.0009*
Day 43, average tumor volume (mm³)	-	2499 ± 222	-	1665 ± 245
P value (day 43)	-	-	-	0.036^#
Day 44, average tumor volume (mm³)	-	2607 ± 247	-	1820 ± 245
P value (day 44)	-	-	-	0.06^#
Rapamycin (5 days per week)	-	8 mg/kg per day	-	8 mg/kg per day
Sorafenib (5 days per week)	-	-	60 mg/kg per day	60 mg/kg per day